Both companies may succeed in this industry.

Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on ...

This biotech has candidates in late-stage clinical development.

Eli Lilly looks undervalued as earnings forecasts rise and GLP-1 catalysts near. Read the full analysis here of LLY stock.

Although the stock is trading at a premium valuation, the company’s outstanding operational performance, strong financial ...

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition ...

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

The company got some bad news to start 2026.

Eli Lilly is getting its hands on a promising pipeline candidate thanks to an acquisition. The stock may not gain much more ...

Now, it’s worth noting Stock Advisor’s total average return is 949 % — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

Both companies now aim to win in the oral weight loss drug market.